Highlights Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-09 EDT			5-day change	1st Jan Change
6.78 ^USD	-5.17%		+6.44%	+104.22%

05-07	HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating	MT
05-06	Rani Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rani Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-20	CI
Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111)	02-05	CI
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Regarding A Imimolecular Triagonist Molecule Delivered Via Endoscope	12-14	CI
Rani Therapeutics Stock Climbs After Share Purchase by CEO	12-01	MT
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Rani Therapeutics Holdings, Inc. Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform	11-01	CI
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Supporting the Safety and Tolerability of the RaniPill® Drug Delivery Platform Following 60-Day Repeat Administration	23-10-25	CI
Rani Therapeutics Holdings, Inc. Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study	23-10-19	CI
Rani Therapeutics Holdings, Inc. Initiates Phase 1 Study of Rt-111 (Ranipill® Containing Ustekinumab Biosimilar, Ct-P43)	23-09-18	CI
Rani Therapeutics Holdings, Inc. Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies	23-09-07	CI
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
RANI THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-22	AQ
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update	23-03-22	AQ
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-22	CI
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-22	CI
Celltrion and Rani Therapeutics Holdings, Inc. Partner on Development of Oral Monoclonal Antibody Treatment	23-01-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Highlights

Filters